These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 11762035)

  • 1. [Somatostatin analogue (octreotide)].
    Sano K; Makuuchi M
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
    [No Abstract]   [Full Text] [Related]  

  • 2. Octreotide and hepatocellular carcinoma.
    Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
    Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
    [No Abstract]   [Full Text] [Related]  

  • 3. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
    Allgaier HP; Becker G; Blum HE
    Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
    [No Abstract]   [Full Text] [Related]  

  • 4. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma.
    Borbath I; Horsmans Y
    Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712
    [No Abstract]   [Full Text] [Related]  

  • 5. Octreotide treatment of hepatocellular carcinoma.
    Kouroumalis E; Samonakis D; Skordilis P
    Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
    [No Abstract]   [Full Text] [Related]  

  • 6. Octreotide in hepatocellular carcinoma.
    Shouval D
    Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
    Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
    Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
    Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
    Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
    Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
    Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
    Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
    J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
    [No Abstract]   [Full Text] [Related]  

  • 11. Octreotide.
    Lamberts SW; van der Lely AJ; de Herder WW; Hofland LJ
    N Engl J Med; 1996 Jan; 334(4):246-54. PubMed ID: 8532003
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of somatostatin analogs in the management of hepatocellular carcinoma.
    D'Agostino L; Manguso F; Pivonello R; Colao A
    J Endocrinol Invest; 2003; 26(8 Suppl):131-3. PubMed ID: 15233229
    [No Abstract]   [Full Text] [Related]  

  • 13. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
    Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
    Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin and hepatocellular carcinoma.
    Kapadia CR
    Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
    [No Abstract]   [Full Text] [Related]  

  • 16. Somatostatin analogs and hepatocellular carcinoma: Not dead yet?
    Raftery L; O'Neil BH
    Cancer Biol Ther; 2009 Nov; 8(21):2040-1. PubMed ID: 19823044
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma.
    Morris DL
    Cancer; 1996 May; 77(9):1956-7. PubMed ID: 8646698
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortistatin production by HepG2 human hepatocellular carcinoma cell line and distribution of somatostatin receptors.
    Notas G; Kolios G; Mastrodimou N; Kampa M; Vasilaki A; Xidakis C; Castanas E; Thermos K; Kouroumalis E
    J Hepatol; 2004 May; 40(5):792-8. PubMed ID: 15094227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.